agilon health inc
For the period ended Aug 6, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2024 · Filed Aug 6, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · ADJUSTED EBITDA
ADJUSTED EBITDA
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net income (loss)(1) | $(30,662) | $(16,795) | $(36,696) | $(836) |
| (Income) loss from discontinued operations, net of income taxes | — | 769 | 9,281 | (5,239) |
| Interest expense | 1,697 | 1,555 | 2,981 | 3,048 |
| Income tax expense (benefit) | 417 | 1,073 | 284 | (686) |
| Depreciation and amortization | 5,907 | 4,279 | 11,751 | 7,233 |
| Severance and related costs | 868 | — | 3,283 | 188 |
| Stock-based compensation expense | 18,207 | 19,446 | 35,116 | 33,031 |
| EBITDA adjustments related to equity method investments | 1,404 | 2,757 | 5,306 | 4,724 |
| Other(2) | (668) | (615) | (5,082) | (4,956) |
| Adjusted EBITDA | $(2,830) | $12,469 | $26,224 | $36,507 |
(1)Includes direct geography entry costs, including investments to develop and expand our platform and costs in geographies that are in implementation and are not yet generating revenue and investments to grow existing markets. For the three months ended June 30, 2024 and 2023, (i) $18,000 and $7.7 million, respectively, are included in other medical expenses and (ii) $4.8 million and $11.3 million, respectively, are included in general and administrative expenses. For the six months ended June 30, 2024 and 2023, (i) $0.6 million and $10.0 million, respectively, are included in other medical expenses and (ii) $15.3 million and $20.6 million, respectively, are included in general and administrative expenses.
(2)Includes interest income and transaction-related costs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.